Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the "Private Placement") of up to 20,000,000 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of up to $11,000,000. Each Unit will be comprised of one common share (each, a "Share ...

Core Insights - Defence Therapeutics Inc. is advancing its Accum® platform for antibody-drug conjugate (ADC) applications, as discussed in a recent Scientific Advisory Board meeting [1][2]. Group 1: Scientific Advisory Board Meeting - The meeting on January 30, 2026, focused on enhancing the strategic positioning of Accum® for ADC applications, bringing together experts in ADC chemistry, experimental design, and value creation [1][2]. - The discussion aimed to identify critical scientific questions, refine development priorities, and align data generation with the expectations of future clinical and pharmaceutical partners [2]. Group 2: Expert Contributions - Contributions from experts such as Rob Leanna, Danny Chui, and Brendan Hussey provided insights into ADC development, drug-linker chemistry, and clinical advancement, guiding the next phase of Accum® development [3]. - The multidisciplinary dialogue is expected to refine the Accum® ADC development roadmap, aligning platform capabilities with clinical development requirements and partnering considerations [4]. Group 3: Company Overview - Defence Therapeutics is committed to enhancing cancer treatment efficacy and safety through its Accum® precision drug delivery platform, aiming to improve the potency of ADCs and reduce side effects [5]. - The company seeks to collaborate with pharmaceutical and biotech partners to bring transformative therapies to patients [5].

Core Viewpoint - Defence Therapeutics Inc. is enhancing its collaboration with Canadian Nuclear Laboratories to accelerate its radiopharmaceutical program, which is a key part of its strategy to develop effective cancer therapies [1][5]. Group 1: Collaboration and Program Development - Defence has been working with CNL on an Accum®-enhanced radio-immunoconjugate program, which is nearing a critical stage for candidate selection and preparation for first-in-human clinical studies [2]. - The collaboration is expanding to include multiple other radioisotope programs utilizing Defence's proprietary Accum®, allowing for rapid expansion of its radiopharmaceutical portfolio [3]. Group 2: Technology and Efficacy - Radiopharmaceutical therapies require precise intracellular and nuclear localization to maximize efficacy, which Defence's Accum® platform facilitates by enabling active transport to the cell nucleus [4]. - This technology aims to enhance the potency of targeted radiotherapies while reducing toxicity, thereby improving treatment outcomes for cancer patients [4]. Group 3: Strategic Importance - The collaboration with CNL is described as a cornerstone of Defence's radiopharmaceutical strategy, positioning it alongside the company's antibody-drug conjugate (ADC) program as a top development priority [5]. - The partnership leverages CNL's nuclear science expertise to advance Defence's proprietary pipeline in radiopharmaceuticals, aiming to transform advanced biologics into safer, more effective cancer therapies [5].

Core Perspective - Defence Therapeutics Inc. is evolving its corporate positioning to focus on its proprietary Accum® platform, aimed at enhancing intracellular drug delivery for cancer treatments [1][2][4] Group 1: Company Strategy - The company is prioritizing the Accum® platform through a dual strategy that combines internal R&D programs with strategic partnerships in the biotech and pharmaceutical sectors [3][4] - Accum® is designed to improve cellular uptake and payload release, increasing therapeutic potency at lower doses while potentially reducing toxicity [2][3] Group 2: Commitment to Precision Oncology - Defence Therapeutics aims to transform therapies traditionally used in later lines into safer, more effective first-line treatment options [3] - The company emphasizes collaboration and the translation of cutting-edge science into life-changing treatments, with a business model focused on generating scalable value for partners and long-term value for shareholders [4][5]

Corporate Governance - Defence Therapeutics Inc. held its annual general meeting where shareholders approved all matters presented, including setting the number of directors at five and electing the board members with 100% approval [1] Stock Options and Warrants - The company granted a total of 800,000 stock options to certain directors, officers, and employees, exercisable at a price of $0.82 per Class A Common share for a period of 10 years [2] - An amendment was made to the terms of 967,000 Common Share purchase warrants, extending the expiry date by 12 months and repricing the exercise price to $1.00 per Common Share [3] Marketing Engagement - Defence entered into a two-month online marketing agreement with i2i Marketing Group for a total cash consideration of USD$300,000, with $50,000 paid upfront and the remainder contingent upon completion of conditions [4] Company Overview - Defence Therapeutics is a publicly-traded biotechnology company focused on engineering next-generation ADC products using its proprietary ACCUM® technology, which enhances the precision delivery of biologics to target cells, improving efficacy and market opportunities [6]

Core Insights - Defence Therapeutics Inc. has established its inaugural Scientific Advisory Board (SAB) to enhance its Accum®-Antibody drug conjugate (ADC) program, which has shown significant laboratory validation results [2][3][9] Group 1: Scientific Advisory Board Formation - The SAB consists of experts Rob Leanna, Danny Chui, and Brendan Hussey, who will provide scientific, technical, and strategic guidance for the company's programs [2][4] - The formation of the SAB aims to strengthen Defence's scientific foundation and support disciplined decision-making as the company advances its Accum® platform [9] Group 2: Accum®-Antibody Drug Conjugate Program - Defence's Accum®-ADC program has achieved laboratory validations, indicating a notable increase in intracellular accumulation and improved efficacy [3] - The SAB will help shape the direction and scientific priorities of the Accum®-enabled ADC programs as they progress towards clinical development [3][9] Group 3: Expertise of SAB Members - Rob Leanna brings extensive experience in ADC and drug-linker chemistry, having previously led development and regulatory strategy at AbbVie Inc. [5] - Danny Chui has over 20 years of experience in therapeutic antibody discovery and ADC development, contributing expertise in antibody engineering and preclinical pharmacology [6] - Brendan Hussey, with a background in biotechnology and investment banking, will align Defence's platform with market opportunities and partner expectations [7] Group 4: Company Overview - Defence Therapeutics is focused on engineering next-generation ADC products using its proprietary Accum® technology, which enhances the precision delivery of biologics [10] - The Accum® platform aims to improve efficacy and potency for biologics, thereby expanding patient access and market opportunities [10]

Core Insights - Defence Therapeutics Inc. has announced the conversion of its 8% convertible debentures into common shares, totaling 2,607,600 shares upon maturity on November 16, 2025 [1][2] Group 1: Financial Details - The principal amount of $1,476,000 was converted into 2,460,000 shares at a conversion price of $0.60 per share [2] - An aggregate amount of $118,080 of accrued interests was converted into 147,600 shares at $0.80 per share, bringing the total conversion value to $1,594,080 [2] Group 2: Company Overview - Defence Therapeutics is a publicly-traded biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology [3] - The ACCUM® technology allows for precision delivery of ADCs to target cells, enhancing efficacy and potency against cancer [3]

Core Insights - Defence Therapeutics Inc. is advancing its proprietary Accum® technology to enhance antibody-drug conjugates (ADCs) for cancer treatment, aiming to overcome current limitations in ADC efficacy and toxicity [1][5]. Company Developments - The company has successfully engaged with ADC companies at industry conferences, positioning itself as a supplier of its Accum® platform to improve drug delivery precision and reduce toxicity in cancer therapies [2][5]. - Defence has conducted studies demonstrating that its Accum® technology can significantly enhance the potency of ADCs, with a recent study showing a ~20-fold increase in anti-tumor efficacy in mouse models when comparing Accum®-Kadcyla to Kadcyla® alone [4]. Technology and Innovation - The Accum® technology allows for the precise delivery of ADCs in their intact form to target cells, which is expected to lead to increased efficacy and potency against cancer [6]. - The company aims to transform ADC cancer therapies by applying its Accum® technology across various antibodies and indications, establishing itself as a leader in ADC drug delivery [5].

Core Insights - Defence Therapeutics Inc. successfully presented new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, generating significant interest from the scientific and industry communities [2][3]. Company Developments - The presentation highlighted how Accum® enhances intracellular delivery and payload release, improving the potency and therapeutic index of antibody-drug conjugates (ADCs) [3]. - The company plans to expand testing of Accum® across a wider range of commercial and clinical-stage ADCs to validate its potential in enhancing efficacy and patient outcomes [4]. - Defence Therapeutics aims to demonstrate that Accum® can universally enhance ADC performance, regardless of the payload or antibody used, and is engaging with industry partners to accelerate evaluations [5]. Technology Overview - The Accum® technology is designed for precision delivery of ADCs in their intact form to target cells, which can lead to increased efficacy and potency against cancer [6].

Core Insights - Defence Therapeutics Inc. has announced promising preclinical in vivo results for its Accum®-Kadcyla, a novel version of Kadcyla® targeting HER2-positive breast cancer, showcasing a significant increase in anti-tumor efficacy [1][2][5] Study Results - Accum®-Kadcyla exhibited approximately a 20-fold increase in anti-tumor efficacy compared to Kadcyla® when administered at the same dose of 0.5 mg/kg, with significant tumor growth inhibition observed [2] - The study reported a durable and near-complete response in most mice treated with Accum®-Kadcyla, while Kadcyla® showed no effect at the same dosage [2] - All animals in the Accum®-Kadcyla group survived the study duration without signs of toxicity, indicating excellent tolerability [2] Implications for Patients and the Industry - The enhanced efficacy at lower doses could lead to reduced toxicity and side effects, addressing a major limitation of current ADC therapies, potentially allowing for a shift from second-line to first-line treatment options for patients [5][6] - The results validate the Accum® platform's ability to improve intracellular delivery and potency of ADCs by overcoming endosomal entrapment, thus enabling more efficient drug release and tumor killing [5][6] Next Steps and Commercial Outlook - Following these results, Defence Therapeutics plans to expand its Accum®-ADC program to additional HER2-positive and HER2-low tumor models and engage in discussions with potential pharmaceutical partners [7]